Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
about
Stress triggers coronary mast cells leading to cardiac eventsDietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and CaucasiansLipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health StudyReplacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.Age as a modulator of inflammatory cardiovascular risk factors.Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction.Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patientsLipoprotein-associated phospholipase A₂ mass level is increased in elderly subjects with type 2 diabetes mellitus.Biomarkers of inflammation and oxidative stress in atherosclerosis.Influence of periodontal intervention therapy on risk of cardiovascular disease.From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population.Evidence that periodontal treatment improves biomarkers and CVD outcomes.Phylogenetic and structural analysis of the phospholipase A2 gene family in vertebratesPlatelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products.Evidence that periodontal treatment improves biomarkers and CVD outcomes.
P2860
Q27022598-68AC599F-B236-4503-9C13-3941288EF8FDQ33666216-EC30F706-1E6B-4AF3-814A-54821F3BB49CQ33829154-8ABE0F61-F291-4F2C-BB44-AD16626EC678Q33849524-6D51A420-7A10-46CB-B434-910241A678BEQ33895897-38FEB67F-DCA6-45D5-B0B5-D14B50E7623AQ33945132-F22F880D-C8A9-488C-8016-7818DB076383Q34167997-F892BE68-7888-4250-9586-31BB5E2112E7Q34384281-70042D11-BBBA-467C-B5FC-61A06EC3DA30Q35171257-9E718AC4-C0A8-4802-8284-EDCBC7DAD427Q36269180-7FA824AB-C497-463C-A4E3-7ED4B95D7EB8Q36913022-650421A3-FE84-4544-9D49-FFDF1AC711EBQ37210477-DD044709-E098-4CCA-B0A1-EE80764E3396Q37445865-F04F701B-7069-4D23-A04D-31194042E2E4Q37616607-CF7E6562-87E5-4275-B41D-3155B1E811B7Q37730748-82D548FD-FE5D-4302-ACFE-1E16734F48B6Q37765284-B500F78F-C55F-4A93-9192-CF53BBA910F8Q37866360-0E85D5F1-297F-48D4-A5CD-7399D87221B6Q37881966-2A1E26C3-5A73-4060-B375-E0D76BE12314Q38102723-020B6337-6AB6-40F1-9E52-D1471B2BA6A1Q41645827-07020388-DCC7-4BD7-A8AA-F1E3C643FB08Q45085322-0442DEFF-E3FE-4C2E-AEA2-62C6BD3AE031Q49346082-B1EDA563-4EEC-4C3F-AEB7-8D61778F83C4Q51029740-070BC0CB-0E2E-47EF-ADCE-C15079A99806
P2860
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@ast
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@en
type
label
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@ast
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@en
prefLabel
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@ast
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@en
P1476
Lipoprotein-associated phospho ...... e) and cardiovascular disease.
@en
P2093
Chris J Packard
Muriel J Caslake
P304
P356
10.1097/00041433-200308000-00002
P577
2003-08-01T00:00:00Z